Persistence of SARS-CoV-2 has been proposed as a biological driver of Long COVID, a disabling chronic illness with no proven treatments. We conducted an exploratory, placebo-controlled, double-blind, 2:1 randomized mechanistic trial (NCT05877508) of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participa...
M. Peluso, Dylan Ryder, T. Dalhuisen et al.· Nature Communications· 0 citations
A tissue-based transcriptional environment in which SARS-CoV-2 activates innate myeloid immune signaling, driving chronic inflammation while simultaneously downregulating pathways responsible for immune-mediated clearance of infected cells is identified, including antigen presentation, phagocytosis, cytotoxic immune ce...
B. LaFranchi, David P. Maison, J. Vinden et al.· bioRxiv· 0 citations
CD4+ T cell count influences antibody persistence, while the CD4/CD8 ratio affects initial antibody magnitude and Tfh cell frequencies, highlighting complementary roles in shaping vaccine responses in PLWH.
Roser Navarro-Soler, M. J. Heise, T. Dalhuisen et al.· Journal of Acquired Immune D...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.